Patents Assigned to Boston Biomedical Research Institute, Inc.
  • Patent number: 8759098
    Abstract: Embodied herein are methods of reprogramming somatic cells or tissue stem cells to a more multipotent state or even a pluripotent state, the methods do not involve gene transfer of master transcription factor genes/proteins. The methods are also useful for rapid and efficient cloning of induced pluripotent stem cells after gene transfer of master transcription factor genes/proteins.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: June 24, 2014
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: James L. Sherley
  • Publication number: 20130004965
    Abstract: This invention provides methods of determining the number and percent of tissue specific stem cells (TSSCs) in a sample of cells, a population of cells or a sample of tissue. The methods rely on detecting the pattern-specific asymmetric localization of asymmetric self-renewal associated (ASRA) proteins or cell cycle specific proteins (CSSP) in cell undergoing asymmetrical self-renewal, which is a characteristic of TSSCs. The methods can be applied to any situations in which the percent of TSSC is desired such as laboratory research on adult stem cells, in drug development tests, prognostic indicator and therapeutic index, as a diagnostic and prognostic indicator and in monitoring TSSC expansion, e.g., in cell manufacturing processes.
    Type: Application
    Filed: December 3, 2010
    Publication date: January 3, 2013
    Applicant: BOSTON BIOMEDICAL RESEARCH INSTITUTE, INC.
    Inventor: James L. Sherley
  • Publication number: 20120295351
    Abstract: Embodied herein are methods of reprogramming somatic cells or tissue stem cells to a more multipotent state or even a pluripotent state, the methods do not involve gene transfer of master transcription factor genes/proteins. The methods are also useful for rapid and efficient cloning of induced pluripotent stem cells after gene transfer of master transcription factor genes/proteins.
    Type: Application
    Filed: December 3, 2010
    Publication date: November 22, 2012
    Applicant: BOSTON BIOMEDICAL RESEARCH INSTITUTE, INC.
    Inventor: James L. Sherley
  • Patent number: 5523210
    Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and in enzymatic assays.
    Type: Grant
    Filed: June 17, 1992
    Date of Patent: June 4, 1996
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: Henry P. Paulus
  • Patent number: 5292668
    Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and in enzymatic assays.
    Type: Grant
    Filed: December 5, 1990
    Date of Patent: March 8, 1994
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: Henry P. Paulus
  • Patent number: 4474742
    Abstract: Toxicity of asbestos is reduced by treating it with non-mutagenic non-toxic hydroxamic acid iron-chelating agents.
    Type: Grant
    Filed: February 17, 1983
    Date of Patent: October 2, 1984
    Assignees: Boston Biomedical Research Institute, Inc., The General Hospital Corporation
    Inventors: Philip Graceffa, Sigmund A. Weitzman
  • Patent number: 4444878
    Abstract: A homogenous sample of identical bispecific antibody determinants, each determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being specific for a different antigenic determinant and including at least the F(ab') portion of a monoclonal IgG antibody. The bispecific antibody determinants are useful, e.g., in the formation of multilamellar assemblies and enzyme electrodes.
    Type: Grant
    Filed: December 21, 1981
    Date of Patent: April 24, 1984
    Assignee: Boston Biomedical Research Institute, Inc.
    Inventor: Henry P. Paulus